Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Molecular Endocrinology (Baltimore, Md.)
|
August 26, 1998
Positive and negative discrimination of estrogen receptor agonists and antagonists using site-specific DNA recombinase fusion proteins
C Logie, M Nichols, K Myles, et al.
Biotechniques
|
November 26, 1999
Infecting larval arthropods with a chimeric, double subgenomic Sindbis virus vector to express genes of interest
S Higgs, C T Oray, K Myles, et al.
Recent Progress in Hormone Research
|
January 1, 1997
Mineralocorticoid receptors, salt, and hypertension
J W Funder, Z Krozowski, K Myles, et al.
Lancet (London, England)
|
October 25, 1975
Down syndrome and thyroid function in adults
R G Baxter, R G Larkins, F I Martin, et al.
Endocrinology
|
March 17, 2001
The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action
A Bhargava, M J Fullerton, K Myles, et al.
Journal of the American College of Surgeons
|
August 26, 2006
Improved surgeon performance in clinical trials: an analysis of quality assurance audits from the American College of Surgeons Oncology Group
Y Nancy You, Lisa Jacobs, Elizabeth D Martinez, et al.
Molecular and Cellular Endocrinology
|
February 27, 2001
GRKO mice express an aberrant dexamethasone-binding glucocorticoid receptor, but are profoundly glucocorticoid resistant
T J Cole, K Myles, J F Purton, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 19, 2000
The glucocorticoid receptor is essential for induction of cytochrome P-4502B by steroids but not for drug or steroid induction of CYP3A or P-450 reductase in mouse liver
E G Schuetz, W Schmid, G Schutz, et al.
Circulation
|
November 15, 2006
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity
Christopher K Dyke, Steven R Steinhubl, Neal S Kleiman, et al.
Circulation
|
July 28, 2010
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention
Mauricio G Cohen, Drew A Purdy, Joseph S Rossi, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Molecular Endocrinology (Baltimore, Md.)
|
August 26, 1998
Positive and negative discrimination of estrogen receptor agonists and antagonists using site-specific DNA recombinase fusion proteins
C Logie, M Nichols, K Myles, et al.
Biotechniques
|
November 26, 1999
Infecting larval arthropods with a chimeric, double subgenomic Sindbis virus vector to express genes of interest
S Higgs, C T Oray, K Myles, et al.
Recent Progress in Hormone Research
|
January 1, 1997
Mineralocorticoid receptors, salt, and hypertension
J W Funder, Z Krozowski, K Myles, et al.
Lancet (London, England)
|
October 25, 1975
Down syndrome and thyroid function in adults
R G Baxter, R G Larkins, F I Martin, et al.
Endocrinology
|
March 17, 2001
The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action
A Bhargava, M J Fullerton, K Myles, et al.
Journal of the American College of Surgeons
|
August 26, 2006
Improved surgeon performance in clinical trials: an analysis of quality assurance audits from the American College of Surgeons Oncology Group
Y Nancy You, Lisa Jacobs, Elizabeth D Martinez, et al.
Molecular and Cellular Endocrinology
|
February 27, 2001
GRKO mice express an aberrant dexamethasone-binding glucocorticoid receptor, but are profoundly glucocorticoid resistant
T J Cole, K Myles, J F Purton, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 19, 2000
The glucocorticoid receptor is essential for induction of cytochrome P-4502B by steroids but not for drug or steroid induction of CYP3A or P-450 reductase in mouse liver
E G Schuetz, W Schmid, G Schutz, et al.
Circulation
|
November 15, 2006
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity
Christopher K Dyke, Steven R Steinhubl, Neal S Kleiman, et al.
Circulation
|
July 28, 2010
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention
Mauricio G Cohen, Drew A Purdy, Joseph S Rossi, et al.
Page
of 3